The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged. Boston Scientific gave a mixed updated full-year forecast.

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

but investors pulled back due to a "pause" in a trial of key product in development. Boston Scientific's (NYSE: BSX) stock was down just over 1% as of 3:30, after it fell as far as 4% earlier in ...

“We continue to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position us well for the long term.” Boston Scientific increased its full-year ...

Credit: Sundry Photography via Shutterstock. Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations” ...

Vijay Kumar, an analyst at Evercore, said in an interview that Farapulse is likely Boston Scientific’s most important product from Wall Street’s perspective. The pulsed field ablation system ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...

The Farapulse Farawave catheter and Faraview software. [Image courtesy of Boston Scientific] Boston Scientific (NYSE: BSX) + announced today that it received FDA approval for its navigation ...

Boston Scientific is launching the Farawave Nav ablation catheter and Faraview software to treat atrial fibrillation in the U.S. · MedTech Dive · Courtesy of Boston Scientific Boston Scientific ...

Medical-products company Boston Scientific reported third-quarter results before market open Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.